Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of alfentanil. 1999

T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
Department of Anesthesia and Critical Care Medicine, University of Bonn, Germany. bouillon@leland.stanford.edu

BACKGROUND Although respiratory depression is the most well-known and dangerous side effect of opioids, no pharmacokinetic-pharmacodynamic model exists for its quantitative analysis. The development of such a model was the aim of this study. METHODS After institutional approval approval and informed consent were obtained, 14 men (American Society of Anesthesiologists physical status I or II; median age, 42 yr [range, 20-71 yr]; median weight, 82.5 kg [range, 68-108 kg]) were studied before they underwent major urologic surgery. An intravenous infusion of alfentanil (2.3 microg x kg(-1) x min(-1)) was started while the patients were breathing oxygen-enriched air (fraction of inspired oxygen [FIO2 = 0.5) over a tightly fitting continuous positive airway pressure mask. The infusion was discontinued when a cumulative dose of 70 microg/kg had been administered, the end-expiratory partial pressure of carbon dioxide (PE(CO2) exceeded 65 mmHg, or apneic periods lasting more than 60 s occurred During and after the infusion, frequent arterial blood samples were drawn and analyzed for the concentration of alfentanil and the arterial carbon dioxide pressure (PaCO2). A mamillary two-compartment model was fitted to the pharmacokinetic data. The PaCO2 data were described by an indirect response model The model accounted for the respiratory stimulation resulting from increasing PaCO2. The model parameters were estimated using NONMEM. Simulations were performed to define the respiratory response at steady state to different alfentanil concentrations. RESULTS The indirect response model adequately described the time course of the PaCO2. The following pharmacodynamic parameters were estimated (population means and interindividual variability): EC50, 60.3 microg/l (32%); the elimination rate constant of carbon dioxide (Kel), 0.088 min(-1) (44%); and the gain in the carbon dioxide response, 4(28%) (fixed according to literature values). Simulations revealed the pronounced role of PaCO2 in maintaining alveolar ventilation in the presence of opioid. CONCLUSIONS The model described the data for the entire opioid-PaCo2 response surface examined. Indirect response models appear to be a promising tool for the quantitative evaluation of drug-induced respiratory depression.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D012119 Respiration The act of breathing with the LUNGS, consisting of INHALATION, or the taking into the lungs of the ambient air, and of EXHALATION, or the expelling of the modified air which contains more CARBON DIOXIDE than the air taken in (Blakiston's Gould Medical Dictionary, 4th ed.). This does not include tissue respiration ( Breathing
D002245 Carbon Dioxide A colorless, odorless gas that can be formed by the body and is necessary for the respiration cycle of plants and animals. Carbonic Anhydride,Anhydride, Carbonic,Dioxide, Carbon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D015760 Alfentanil A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. Alfentanyl,Alfenta,Alfentanil Hydrochloride,Fanaxal,Limifen,R-39209,Rapifen,R 39209,R39209

Related Publications

T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
May 2007, The Journal of pharmacology and experimental therapeutics,
T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
November 2006, The Journal of pharmacology and experimental therapeutics,
T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
October 1997, Journal of pharmacological and toxicological methods,
T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
October 2001, Anesthesia and analgesia,
T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
November 2003, Acta anaesthesiologica Scandinavica,
T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
January 2000, Archives of medical research,
T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
January 1996, Methods and findings in experimental and clinical pharmacology,
T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
May 2005, Journal of pain and symptom management,
T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
February 1997, Journal of pharmacokinetics and biopharmaceutics,
T Bouillon, and C Schmidt, and G Garstka, and D Heimbach, and D Stafforst, and H Schwilden, and A Hoeft
December 2019, Anesthesiology,
Copied contents to your clipboard!